Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2-Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial

被引：0

作者：

Welslau, Manfred ^{[1
]}

Potthoff, Karin ^{[2
]}

Zaiss, Matthias ^{[3
]}

Mueller, Lothar ^{[4
]}

Brucker, Cosima ^{[5
]}

Salat, Christoph ^{[6
]}

Untch, Michael ^{[7
]}

Meiler, Johannes ^{[8
]}

Lueftner, Diana ^{[9
]}

Welt, Anja ^{[10
]}

Doerfel, Steffen ^{[11
]}

Hagen, Volker ^{[12
]}

Stein, Alexander ^{[13
]}

Liersch, Ruediger ^{[14
]}

Kuhn, Thomas ^{[15
]}

Siebenbach, Hans Ulrich ^{[16
]}

Bing, Gerlinde ^{[17
]}

Vannier, Corinne ^{[2
]}

Marschner, Norbert ^{[2
,18
]}

Gratzke, Katja ^{[2
]}

机构：

[1] Klinikum Aschaffenburg Alzenau, Med Klin 2, Aschaffenburg, Germany

[2] IOMED, Med Dept, Freiburg, Germany

[3] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany

[4] Onkol UnterEms, Leer, Germany

[5] Univ Klin Paracelsus Med Privatunivers, Klin Frauenheilkunde & Geburtshilfe, Klinikum Nurnberg, Nurnberg, Germany

[6] Med Zent Hamatol & Onkol Munchen MVZ GmbH, Arztehaus Nymphenburg, Munich, Germany

[7] HELIOS Klinikum Berlin Buch, Gynakol, Berlin, Germany

[8] Klin Dr Hancken, Hamatol & Onkol, Klin D, Stade, Germany

[9] Med Hsch Brandenburg, Immanuel Klin Mark Schweiz, Rudersdorf, Germany

[10] Univ Klinikum Essen, Innere Klin, Tumorforschung, Essen, Germany

[11] Onkozentrum Dresden Freiberg, Dresden, Germany

[12] St Johannes Hosp, Innere Med 2, Dortmund, Germany

[13] Eppendorf HOPE, Hamatol Onkol Praxis, Hamburg, Germany

[14] GEHO Dres, Munster, Germany

[15] Kuhn & Beldermann, Gynakol Onkol Gemeinschaftspraxis Dres, Stuttgart, Germany

[16] iOMED, Biostat, Freiburg, Germany

[17] IOMED, Clin Operat, Freiburg, Germany

[18] Univ Freiburg Klinikum, Med Klin 1, Freiburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2025年 / 48卷 / 1-2期

关键词：

Palbociclib; Endocrine therapy; Letrozole; Anastrozole; Exemestane; Fulvestrant; BREAST-CANCER; LETROZOLE;

D O I：

10.1159/000542459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated. Methods: The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), safety, and quality of life. Data were analyzed with descriptive statistics. Results: Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n = 157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n = 219), PFS was 20.1 months (95% CI 14.6-24.0), and OS was 40.9 months (95% CI 35.1-49.2). The most common grade 3/4 adverse event was neutropenia (33.4% n = 77). There were no treatment-related deaths. Conclusion: The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.

引用

页码：14 / 24

页数：11

共 13 条

[1]

AWMF-S3-Leitlinie Mammakarzinom, 2021, AWMF LEITLIN REGIST

[2] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].

Cardoso, F. ;

Senkus, E. ;

Costa, A. ;

Papadopoulos, E. ;

Aapro, M. ;

Andre, F. ;

Harbeck, N. ;

Aguilar Lopez, B. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Boers-Doers, C. B. ;

Cardoso, M. J. ;

Carey, L. A. ;

Cortes, J. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. S. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Johnston, S. R. D. ;

Kaufmann, B. ;

Koppikar, S. ;

Krop, I. E. ;

Mayer, M. ;

Nakigudde, G. ;

Offersen, B. V. ;

Ohno, S. ;

Pagani, O. ;

Paluch-Shimon, S. ;

Penault-Llorca, F. ;

Prat, A. ;

Rugo, H. S. ;

Sledge, G. W. ;

Spence, D. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Xu, B. ;

Norton, L. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657

[3] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3. [J].

Cristofanilli, Massimo ;

Rugo, Hope S. ;

Im, Seock-Ah ;

Slamon, Dennis J. ;

Harbeck, Nadia ;

Bondarenko, Igor ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Iwata, Sherene Loi Hiroji ;

O'Leary, Ben ;

Bananis, Eustratios ;

Liu, Yuan ;

Huang, Xin ;

Kim, Sindy ;

Lechuga, Mariajose ;

Turner, Nicholas C. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[4] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[5]

Finn RS, 2022, J CLIN ONCOL, V40

[6] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[7] Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers [J].

Finn, Richard S. ;

Aleshin, Alexey ;

Slamon, Dennis J. .

BREAST CANCER RESEARCH, 2016, 18

[8] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].

Finn, Richard S. ;

Crown, John P. ;

Lang, Istvan ;

Boer, Katalin ;

Bondarenko, Igor M. ;

Kulyk, Sergey O. ;

Ettl, Johannes ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav ;

Thummala, Anu R. ;

Voytko, Nataliya L. ;

Fowst, Camilla ;

Huang, Xin ;

Kim, Sindy T. ;

Randolph, Sophia ;

Slamon, Dennis J. .

LANCET ONCOLOGY, 2015, 16 (01) :25-35

[9] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[10] CDK4/6 inhibitors: The Devil is in the Detail [J].

Magge, Tara ;

Rajendran, Sneha ;

Brufsky, Adam M. ;

Foldi, Julia .

CURRENT ONCOLOGY REPORTS, 2024, 26 (06) :665-678

← 1 2 →